Read by QxMD icon Read

PET-CT lung cancer

Zekiye Hasbek, Ömer Tamer Doğan, İsmail Sarı, Birsen Yücel, Mehmet Metin Şeker, Bülent Turgut, Serdar Berk, Yavuz Siliğ
OBJECTIVE: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUVmax), SUVave, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size. METHODS: Serum anti-p53 Ab level was studied in three groups...
October 5, 2016: Molecular Imaging and Radionuclide Therapy
Sara Sheikhbahaei, Esther Mena, Anusha Yanamadala, Siddaling Reddy, Lilja B Solnes, Jason Wachsmann, Rathan M Subramaniam
OBJECTIVE: The purpose of this article is to summarize the evidence regarding the role of FDG PET/CT in treatment response assessment and surveillance of lung cancer and to provide suggested best practices. CONCLUSION: FDG PET/CT is a valuable imaging tool for assessing treatment response for patients with lung cancer, though evidence for its comparative effectiveness with chest CT is still evolving. FDG PET/CT is most useful when there is clinical suspicion or other evidence for disease recurrence or metastases...
October 11, 2016: AJR. American Journal of Roentgenology
Viviana De Rosa, Francesca Iommelli, Marcello Monti, Ciro Gabriele Mainolfi, Rosa Fonti, Silvana Del Vecchio
BACKGROUND: The two main mechanisms of resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) are the occurrence of T790M secondary mutation in the kinase domain of EGFR and MET amplification. The aim of the present study was to test whether early changes of (18)F-fluorodeoxyglucose ((18)F-FDG) uptake in animal models bearing erlotinib-resistant NSCLC may have different imaging patterns of response to erlotinib depending on the molecular mechanisms underlying resistance...
December 2016: EJNMMI Research
Hiroyuki Matsuzaki, Soichiro Ishihara, Kazushige Kawai, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Shigeru Yamada, Toshiaki Watanabe
BACKGROUND: The need for surveillance of rare late recurrence of rectal cancer has not yet been established. Local control of unresectable skeletal metastasis is important for palliation of symptoms and support for systemic chemotherapy. CASE PRESENTATION: A Japanese man underwent preoperative pelvic irradiation (50.4 Gy/28 Fr) and low anterior resection at the age of 57 years. The pathological stage was II (T3N0M0). Nine years after the surgery, his carcinoembryonic antigen (CEA) level showed rapid elevation, although he had no symptoms...
December 2016: Surgical Case Reports
Naomi E Verstegen, Alexander P W M Maat, Frank J Lagerwaard, Marinus A Paul, Michel I Versteegh, Joris J Joosten, Willem Lastdrager, Egbert F Smit, Ben J Slotman, Joost J M E Nuyttens, Suresh Senan
INTRODUCTION: The literature on surgical salvage, i.e. lung resections in patients who develop a local recurrence following stereotactic ablative radiotherapy (SABR), is limited. We describe our experience with salvage surgery in nine patients who developed a local recurrence following SABR for early stage non-small cell lung cancer (NSCLC). METHODS: Patients who underwent surgical salvage for a local recurrence following SABR for NSCLC were identified from two Dutch institutional databases...
October 3, 2016: Radiation Oncology
Nermina Beslic, Amera Sadija, Timur Ceric, Renata Milardovic, Sejla Ceric, Semra Cavaljuga
INTRODUCTION: Positron emission tomography/computed tomography (PET-CT) is very sensitive for diagnosis of recurrent NSCLC and has a significant impact on change of management. Preliminary data suggest superiority of PET-CT comparing to CT alone for lung cancer restaging. MATERIALS AND METHODS: This is a retrospective study which aim is to validate usage of PET-CT in suspected non-small cell lung carcinoma recurrence and its impact on further patient management...
July 16, 2016: Acta Informatica Medica: AIM
Julio Francisco Jiménez-Bonilla, Remedios Quirce, I Martínez-Rodríguez, María De Arcocha-Torres, José Manuel Carril, Ignacio Banzo
Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide and its prognosis remains poor. Molecular imaging with (18)F-FDG PET/CT can metabolically characterize the nature of lesions as benign or malignant, allowing a better staging at the diagnosis of this kind of patient. This advantage can also be applied in the re-staging due to the suspicion of recurrent disease. Many patients have a recurrence of the disease, including surgically treated patients. In the current context, with new personalized oncological treatments, the surveillance for recurrence and its accurate diagnosis are crucial to improve their survival...
September 30, 2016: Diagnostics
Zhi-Xin Qiu, Yue Cheng, Dan Liu, Wei-Ya Wang, Xia Wu, Wei-Lu Wu, Wei-Min Li
BACKGROUND: Lung nodules are being detected at an increasing rate year by year with high-resolution computed tomography (HRCT) being widely used. Ground-glass opacity nodule is one of the special types of pulmonary nodules that is confirmed to be closely associated with early stage of lung cancer. Very little is known about solitary ground-glass opacity nodules (SGGNs). In this study, we analyzed the clinical, pathological, and radiological characteristics of SGGNs on HRCT. METHODS: A total of 95 resected SGGNs were evaluated with HRCT scan...
2016: Therapeutics and Clinical Risk Management
Koji Morita, Takahiko Sakamoto, Shuji Ota, Hideo Masugi, Ikumi Chikuta, Yamato Mashimo, Naoki Edo, Takuo Tokairin, Nobuhiko Seki, Toshio Ishikawa
It has been shown that metastases to the thyroid from extrathyroidal malignancies occur as solitary or multiple nodules, or may involve the whole thyroid gland diffusely. However, diffuse metastasis of gastric cancer to the thyroid is extremely rare. Here, we report a case of a 74-year-old woman with diffuse infiltration of gastric adenocarcinoma (signet-ring-cell carcinoma/poorly differentiated adenocarcinoma) cells in the thyroid. The pathological diagnosis was made based on upper gastrointestinal endoscopy with biopsy and fine-needle aspiration cytology of the thyroid...
October 1, 2016: Journal of Medical Ultrasonics
E Coche
Lung tumor response to therapy may be evaluated in most instances by morphological criteria such as RECIST 1.1 on computed tomography (CT) or magnetic resonance imaging (MRI). However, those criteria are limited because they are based on tumoral dimensional changes and do not take into account other morphologic criteria such as density evaluation, functional or metabolic changes that may occur following conventional or targeted chemotherapy. New techniques such as dual-energy CT, PET-CT, MRI including diffusion-weighted MRI has to be considered into the new technical armamentarium for tumor response evaluation...
October 2016: Diagnostic and Interventional Imaging
W V Vogel, M G E H Lam, F A Pameijer, U A van der Heide, J B van de Kamer, M E Philippens, M van Vulpen, M Verheij
AIMS: Functional imaging with positron emission tomography/computed tomography (PET/CT) and multiparametric magnetic resonance (mpMR) is increasingly applied for radiotherapy purposes. However, evidence and experience are still limited, and this may lead to clinically relevant differences in accessibility, interpretation and decision making. We investigated the current patterns of care in functional imaging for radiotherapy in the Netherlands in a care evaluation study. MATERIALS AND METHODS: The availability of functional imaging in radiotherapy centres in the Netherlands was evaluated; features available in >80% of academic and >80% of non-academic centres were considered standard of care...
September 27, 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
Joshua D Schaefferkoetter, Jianhua Yan, Therese Anna Soderlund, David W Townsend, Maurizio Conti, John Kit Chung Tam, Ross Soo, Ivan Tham
Lung cancer remains responsible for more deaths worldwide than any other cancer, but recently there has been a significant shift in the clinical paradigm regarding the initial management of subjects at high risk for this disease. Low dose computed tomography (CT) has demonstrated significant improvements over planar X-ray screening for patient prognoses and is now performed in the U.S. Specificity of this modality, however, is poor and the additional information from positron emission tomorgraphy (PET) has the potential to improve its accuracy...
September 29, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Stephen Sf Yip, John Kim, Thibaud Coroller, Chintan Parmar, Emmanuel Rios Velazquez, Elizabeth Huynh, Raymond Mak, Hugo Jwl Aerts
PURPOSE: Positron emission tomography (PET)-based radiomics has been used to non-invasively quantify the metabolic tumor phenotypes; however, little is known about the relationship between these phenotypes and underlying somatic mutations. This study assessed the association and predictive power of (18)F-FDG-PET-based radiomic features for somatic mutations in non-small cell lung cancer (NSCLC) patients. METHODS: 348 NSCLC patients underwent diagnostic (18)F-FDG-PET/CT scans and were tested for genetic mutations...
September 29, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
N Yin, Z X Wang, Y B Zhu, J Xie, S M Deng, B Zhang, Y W Wu
Objective: To evaluate the clinical value of changes of maximum standardized uptake value (SUVmax) in series (18)F-FDG PET/CT imaging before and after chemotherapy for non-small cell lung cancer. Methods: From July 2008 to July 2014, a total of 18 patients with pathological confirmed advanced NSCLC who received systemic chemotherapy were enrolled.(18)F-FDG PET/CT scans were performed before, 3-4 weeks after 2-4 cycles chemotherapy, 3-4 weeks after the end of chemotherapy for all patients, and added fourth scan for 3 patients 1 year later...
September 20, 2016: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Y Zhou, N Liu, Y Dong, Y Huang, H Lu, J Zheng, X Teng, K Cheng, X Sun, X Hu, W Zhao, S Wang, S Zhu, S Yuan
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Y C Wei, W Zhao, X Hu, Q Yu, S Zhu, S Wang, J Yu, S Gao, S Yuan
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
F M Kong, R K Ten Haken, M Schipper, J Hayman, N Ramnath, K Hassan, M M Matuszak, T Ritter, N Bi, W Wang, M Orringer, K Cease, T S Lawrence, G P Kalemkerian
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
S Gao, N Liu, X Hu, S Wang, Q Yu, H Zhang, W Zhao, W Hou, S Yuan
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
David Jonathan Heineman, Martijn Geert Ten Berge, Johannes Marlene Daniels, Michaël Ignatius Versteegh, Perla Jacqueline Marang-van de Mheen, Michael Wilhelmus Wouters, Wilhelmina Hendrika Schreurs
BACKGROUND: The clinical stage of non-small cell lung cancer (NSCLC) determines the initial treatment, whereas the pathologic stage best determines prognosis and the need for adjuvant treatment. In an era in which stereotactic ablative radiotherapy (SABR) has become an alternative modality to surgical intervention, clinical staging is even more important, because pathologic staging is omitted in the case of SABR. The objective of this study was to determine the concordance between clinical and pathologic stage in routine clinical practice for patients with early-stage NSCLC...
September 21, 2016: Annals of Thoracic Surgery
Tom Konert, Wouter V Vogel, Sarah Everitt, Michael P MacManus, Daniela Thorwarth, Elena Fidarova, Diana Paez, Jan-Jakob Sonke, Gerard G Hanna
BACKGROUND AND PURPOSE: To assess the impact of a standardized delineation protocol and training interventions on PET/CT-based target volume delineation (TVD) in NSCLC in a multicenter setting. MATERIAL AND METHODS: Over a one-year period, 11 pairs, comprised each of a radiation oncologist and nuclear medicine physician with limited experience in PET/CT-based TVD for NSCLC from nine different countries took part in a training program through an International Atomic Energy Agency (IAEA) study (NCT02247713)...
September 20, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"